Cindy Ehrenfreund
About Cindy Ehrenfreund
Cindy Ehrenfreund is the Lead of Specialty Portfolio Strategy for Genetically Defined Diseases at Bristol-Myers Squibb, with over 20 years of strategic marketing experience.
Title and Current Role
Cindy Ehrenfreund currently holds the position of Lead, Specialty Portfolio Strategy in Genetically Defined Diseases at Bristol-Myers Squibb. This role involves developing and executing strategic plans for portfolios targeting genetically defined diseases. Cindy has retired from other professional roles but continues her contributions in this specific capacity at Bristol-Myers Squibb.
Professional Background at Bristol-Myers Squibb
Cindy Ehrenfreund has an extensive history of roles at Bristol-Myers Squibb. She served as Triple Reuptake Inhibitor (TRI) Transition Team Co-lead and Commercial Lead from 2011 to 2014. Prior to that, she was the Director of Alzheimer's Disease Global Commercialization from 2009 to 2011 and Director of Early Neuroscience Global Commercialization from 2007 to 2009. She also held the position of Director for Avapro/Avalide Payer Marketing from 2005 to 2007 and has a background as Marketing Director.
Education and Academic Qualifications
Cindy Ehrenfreund earned her Master of Business Administration (M.B.A.) with a specialization in Marketing from New York University - Leonard N. Stern School of Business. She holds a Bachelor of Arts (B.A.) in Biological Sciences with Honors from Wellesley College, providing her with a strong educational foundation in both business and biological sciences.
Expertise in Strategic Marketing
Cindy Ehrenfreund has over 20 years of experience in strategic and executional marketing at both global and local levels. Her extensive expertise includes driving commercial assessment and valuation of external business development opportunities. She has demonstrated leadership within and across matrix organizations, effectively managing complex projects and ensuring successful outcomes.
Patient-Centric Focus
Cindy Ehrenfreund is passionate about transforming the lives of patients with devastating and rare diseases. Her work has consistently aimed at developing and executing disease-level strategies along with asset-specific early commercialization strategies. She strives to make significant contributions to the healthcare industry through her focused efforts on genetically defined diseases.